Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Annals of the Rheumatic Diseases|July 21, 2021
SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunityDaniel Mrak, Selma Tobudic, Maximilian Koblischke, et al.
Frontiers in Medicine|February 27, 2023
The accelerated waning of immunity and reduced effect of booster in patients treated with bDMARD and tsDMARD after SARS-CoV-2 mRNA vaccinationSelma Tobudic, Elisabeth Simader, Thomas Deimel, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|December 12, 2022
Reduced immunogenicity of BNT162b2 booster vaccination in combination with a tetravalent influenza vaccination: results of a prospective cohort study in 838 health workersHelga Radner, Daniela Sieghart, Anselm Jorda, et al.
Science Signaling|January 23, 2024
NLRP12 interacts with NLRP3 to block the activation of the human NLRP3 inflammasomeJared R Coombs, Alina Zamoshnikova, Caroline L Holley, et al.
Science (New York, N.Y.)|November 17, 2018
LZTR1 is a regulator of RAS ubiquitination and signalingJohannes W Bigenzahn, Giovanna M Collu, Felix Kartnig, et al.
Annals of the Rheumatic Diseases|August 17, 2022
Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-label extension studyDaniel Mrak, Elisabeth Simader, Daniela Sieghart, et al.
Annals of the Rheumatic Diseases|June 21, 2023
Cytokine-directed cellular cross-talk imprints synovial pathotypes in rheumatoid arthritisMaximilian Kugler, Mirjam Dellinger, Felix Kartnig, et al.
Nature|January 7, 2015
SLC38A9 is a component of the lysosomal amino acid sensing machinery that controls mTORC1Manuele Rebsamen, Lorena Pochini, Taras Stasyk, et al.
Nature|May 21, 2020
TASL is the SLC15A4-associated adaptor for IRF5 activation by TLR7-9Leonhard X Heinz, JangEun Lee, Utkarsh Kapoor, et al.
Annals of the Rheumatic Diseases|January 14, 2022
Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trialMichael Bonelli, Daniel Mrak, Selma Tobudic, et al.
Pageof 4